Loading
Everything OnCo dates to 2011: 241 entries, 64 landmarks, 60 papers, 46 papers listed on people's pages and 18 approvals. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
241 dated entries in OnCo fall in 2011: 64 landmarks, 60 papers, 46 papers listed on people's pages, 18 approvals, 13 trials reported, 13 regulatory events, 10 companies founded, 9 technologies, 6 journals founded and 2 laws and regulations.
Of those, 13 to the day and 228 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
mCRPC after docetaxel
Actinic keratosis; superficial and nodular basal cell carcinoma added 2017 (Ameluz)
Relapsed Hodgkin lymphoma and systemic ALCL
ALK-positive metastatic NSCLC
Prevention of skeletal-related events in bone metastases and, later, multiple myeloma; giant cell tumour of bone (Xgeva)
Metastatic breast cancer; liposarcoma (2016)
Progressive pancreatic NETs
Metastatic PDAC (PRODIGE 4 / ACCORD 11; component drugs generic)
Advanced NSCLC after failure of at least one chemotherapy regimen (ICOGEN)
Metastatic melanoma
Recurrent glioblastoma (newly diagnosed 2015)
Adjuvant treatment of melanoma with nodal involvement after complete resection (Sylatron). Discontinued; superseded by adjuvant checkpoint and targeted therapy
Peripheral T-cell lymphoma after ≥1 therapy. Withdrawn 2021 after Ro-CHOP
Intermediate/high-risk myelofibrosis
Progressive pancreatic NETs
Advanced gastric cancer with cisplatin; metastatic colorectal cancer intolerant of other fluoropyrimidines added 2022 (Teysuno)
Symptomatic or progressive medullary thyroid cancer
Unresectable or metastatic BRAF V600E melanoma
The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.
Chronic phase and accelerated phase Philadelphia chromosome positive CML in adults resistant or intolerant to prior therapy that included Gleevec (imatinib).
Metastatic melanoma: first checkpoint inhibitor approved anywhere
Newly diagnosed Philadelphia positive CML in pediatric patients. Confirmed: the accelerated approval of 2006 converted to traditional approval 4.5 years after it was granted.
First approval for medullary thyroid cancer
PMA approval, recurrent glioblastoma
Peripheral T-cell lymphoma in patients who have received at least one prior therapy. Accelerated approval on a surrogate endpoint, with a confirmatory trial required.
Approved with the cobas BRAF V600 companion test, the first melanoma targeted therapy
Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT), or after failure of at least 2 multi-agent chemotherapy regimens in patients who are not ASCT candidates.
Systemic anaplastic large cell lymphoma after failure of at least one multi-agent chemotherapy regimen.
Locally advanced or metastatic NSCLC that is ALK-positive as detected by an FDA-approved test. Accelerated approval on a surrogate endpoint, with a confirmatory trial required.
In combination with paclitaxel for patients who have not received chemotherapy for metastatic HER2 negative breast cancer.
For patients with CD33+ AML in first relapse 60 years of age or older and not candidates for cytotoxic chemotherapy.
For adults with B-cell CLL that has not responded to or progressed during or after treatment with at least one standard alkylating agent containing regimen.
The statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made.
Germany, statute.
United Kingdom, scheme.
The year reported on trial records, with the headline result the record gives.
OS 57.1 vs 40.8 months, HR 0.69.
Median overall survival 14.8 against 10.9 months (hazard ratio 0.65, 95 percent confidence interval 0.54 to 0.77) with abiraterone after docetaxel; PSA response 29 against 6 percen...
GOG-0218 PFS 14.1 vs 10.3 months (HR 0.72); no OS benefit.
Registry record NCT00493181; no result is recorded here.
No overall survival gain from adding cetuximab to oxaliplatin-based first-line chemotherapy, including in KRAS wild-type disease.
Lung cancer mortality reduced 20% (NLST) and 24% in men (NELSON).
In KRAS wild-type disease, progression-free survival hazard ratio 0.567 and response odds ratio 2.551 with cetuximab added.
Median overall survival 11.1 months with FOLFIRINOX against 6.8 months with gemcitabine (hazard ratio 0.57, 95 percent confidence interval 0.45 to 0.73; p below 0.001); progression...
PFS HR 0.35 (pNET) and 0.48 (lung/GI).
Ten-year overall survival 62 against 57 percent (hazard ratio for death with radiotherapy alone 1.17, p=0.03) and disease-specific mortality 4 against 8 percent; benefit confined t...
No overall benefit; node-positive 5-year DFS 65.3% vs 54.7% (HR 0.72) and OS 75.7% vs 66.8% (HR 0.70).
Overall response 79 per cent and complete response 45 per cent after two cycles, one-year overall survival 55 per cent, with grade 4 neutropenia in 92 per cent.
Complete haemoglobin response 72.6% vs 25.3% with placebo (P<0.0001); transfusions after randomisation 13.7% vs 25.3% (P = 0.0277).
The publication year on key paper records.
Donenberg T, Lunn J, Curling D, et al. Breast Cancer Research and Treatment.
Bertotti A, Migliardi G, Galimi F, et al. Cancer Discovery.
Errani C, Zhang L, Sung YS, et al. Genes, chromosomes & cancer.
Slamon D, Eiermann W, Robert N, et al. New England Journal of Medicine.
Sanai N, Polley MY, McDermott MW, et al. Journal of neurosurgery.
Bien E, Godzinski J, Dall'igna P, et al. European Journal of Cancer.
Tiacci E, Trifonov V, Schiavoni G, et al. New England Journal of Medicine.
Chapman PB, Hauschild A, Robert C, et al. New England Journal of Medicine.
Mitsunaga M, Ogawa M, Kosaka N, et al. Nature Medicine.
Friedl P, Alexander S. Cell.
Davies PC, Lineweaver CH. Physical biology.
Van Cutsem E, Köhne CH, Láng I, et al. Journal of Clinical Oncology.
Glunde K, Bhujwalla ZM, Ronen SM. Nature Reviews Cancer.
Conroy T, Desseigne F, Ychou M, et al. New England Journal of Medicine.
de Bono JS, Logothetis CJ, Molina A, et al. New England Journal of Medicine.
Fearon K, Strasser F, Anker SD, et al. The Lancet Oncology.
Kellogg BA, Garrett L, Kovtun Y, et al. Bioconjugate chemistry.
Rothwell PM, Fowkes FG, Belch JF, et al. The Lancet.
Ciarapica R, Miele L, Giordano A, et al. BMC medicine.
Tjulandin SA, Bias P, Elsässer R, et al. Archives of Drug Information.
Cortes J, O'Shaughnessy J, Loesch D, et al. The Lancet.
Kroep JR, Ouali M, Gelderblom H, et al. Annals of Oncology.
Sequist LV, Waltman BA, Dias-Santagata D, et al. Science Translational Medicine.
Osborne RJ, Filiaci V, Schink JC, et al. Journal of Clinical Oncology.
Cardillo TM, Govindan SV, Sharkey RM, et al. Clinical Cancer Research.
Lehmann BD, Bauer JA, Chen X, et al. Journal of Clinical Investigation.
Amary MF, Bacsi K, Maggiani F, et al. The Journal of Pathology.
Cancer Genome Atlas Research Network. Nature.
Dawood S, Merajver SD, Viens P, et al. Annals of Oncology.
Senft C, Bink A, Franz K, et al. The Lancet Oncology.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. CA: A Cancer Journal for Clinicians.
De Roock W, De Vriendt V, Normanno N, et al. The Lancet Oncology.
Stephens PJ, Greenman CD, Fu B, et al. Cell.
Beltran H, Rickman DS, Park K, et al. Cancer Discovery.
Aberle DR, Adams AM, Berg CD, et al. (National Lung Screening Trial Research Team). New England Journal of Medicine.
Wang SJ, Lemieux A, Kalpathy-Cramer J, et al. Journal of Clinical Oncology.
Paskett ED, Harrop JP, Wells KJ. CA: A Cancer Journal for Clinicians.
Yamaguchi M, Kwong YL, Kim WS, et al. Journal of Clinical Oncology.
Crane CH, Varadhachary GR, Yordy JS, et al. Journal of Clinical Oncology.
Agostinis P, Berg K, Cengel KA, et al. CA: A Cancer Journal for Clinicians.
Iozzo RV, Sanderson RD. Journal of cellular and molecular medicine.
Yao JC, Shah MH, Ito T, et al. New England Journal of Medicine.
Gatta G, van der Zwan JM, Casali PG, et al. European Journal of Cancer.
Carver BS, Chapinski C, Wongvipat J, et al. Cancer Cell.
Wu J, Matthaei H, Maitra A, et al. Science Translational Medicine.
Salles G, Seymour JF, Offner F, et al. Lancet.
Jones CU, Hunt D, McGowan DG, et al. New England Journal of Medicine.
Blanc V, Bousseau A, Caron A, et al. Clinical Cancer Research.
Schreiber RD, Old LJ, Smyth MJ. Science.
Oken MM, Hocking WG, Kvale PA, et al. JAMA.
Badwe R, Hawaldar R, Parmar V, et al. Journal of Clinical Oncology.
Collisson EA, Sadanandam A, Olson P, et al. Nature Medicine.
Raymond E, Dahan L, Raoul JL, et al. New England Journal of Medicine.
Thuss-Patience PC, Kretzschmar A, Bichev D, et al. European Journal of Cancer.
Topp MS, Kufer P, Gökbuget N, et al. Journal of Clinical Oncology.
Morris ZS, Wooding S, Grant J. Journal of the Royal Society of Medicine.
Langley RR, Fidler IJ. International journal of cancer.
Soto AM, Sonnenschein C. BioEssays.
Wu J, Jiao Y, Dal Molin M, et al. PNAS.
Bissell MJ, Hines WC. Nature Medicine.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Metastatic castration-resistant prostate cancer
Prostate cancer. Proof that castration-resistant disease is still AR-driven.
Extranodal NK/T-cell lymphoma. The SMILE regimen, built around asparaginase and deliberately free of anthracyclines, was tested in newly diagnosed stage IV, relapsed and refractory...
Non-Hodgkin lymphoma (all types). SMILE reached an overall response of 79 per cent in 38 patients with a disease that resists anthracyclines; PRIMA raised three-year progression-fr...
Neuroendocrine and small-cell prostate cancer
Ovarian cancer
High-grade serous ovarian cancer
Hairy cell leukaemia
Hodgkin lymphoma
Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)
ALK-positive anaplastic large cell lymphoma. The CD30 antibody-drug conjugate was approved for systemic anaplastic large cell lymphoma after failure of previous treatment, on high...
Hodgkin lymphoma
Relapsed and refractory classical Hodgkin lymphoma
BRAF V600-mutant melanoma
Cutaneous squamous cell carcinoma
Advanced cutaneous squamous cell carcinoma
Lung cancer (all types). PLCO randomised 154,901 people to four annual chest X-rays or usual care: 1,213 lung cancer deaths against 1,230 after 13 years.
Invasive carcinoma arising in an intraductal papillary mucinous neoplasm (IPMN-associated carcinoma)
ALK-positive non-small-cell lung cancer
Neuroendocrine tumours
Pancreatoblastoma
Borderline resectable pancreatic ductal adenocarcinoma
Locally advanced unresectable pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma. PRODIGE 4 / ACCORD 11 establishes combination chemotherapy for fit patients.
Pancreatic ductal adenocarcinoma. GNAS R201 in 66% of IPMNs and carried into the invasive cancer; Collisson's classical, quasi-mesenchymal and exocrine-like classes.
Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors
Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6)
HER2-amplified colorectal cancer
Chondrosarcoma
Primary large B-cell lymphoma of the testis. Fifty-three men with stage I or II disease treated with rituximab-containing chemotherapy, methotrexate into the spinal fluid and radio...
Acral melanoma
Mucosal melanoma
Primary cutaneous anaplastic large cell lymphoma. A panel from the EORTC, the International Society for Cutaneous Lymphomas and the United States Cutaneous Lymphoma Consortium set...
Lymphomatoid papulosis. The EORTC, International Society for Cutaneous Lymphomas and United States Cutaneous Lymphoma Consortium panel set out definitions, endpoints and treatment...
Inflammatory breast cancer
Colloid (mucinous non-cystic) carcinoma of the pancreas
Melanoma
Melanoma. Immunotherapy and targeted therapy arrive in the same year.
Skin cancer (all types). The first checkpoint inhibitor and the first BRAF inhibitor, the two routes that transformed melanoma.
Mucinous cystic neoplasm of the pancreas with associated invasive carcinoma (MCN-associated carcinoma)
Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma)
Mesothelioma
Non-Hodgkin lymphoma (all types). An oncogenic MYD88 substitution is found in 29% of activated B-cell-like lymphomas; in the same period CREBBP and EP300 inactivation is found in a...
Prostate cancer. AURKA and MYCN are co-amplified in 40% of neuroendocrine prostate cancers against 5% of adenocarcinomas, and Aurora kinase inhibition switches off the neuroendocri...
Resectable stage I to III non-small-cell lung cancer
Non-small-cell lung cancer
Follicular lymphoma. Two years of maintenance doubles PFS after chemo-immunotherapy.
Metastatic pancreatic ductal adenocarcinoma
Desmoid tumour. French Sarcoma Group and others show frequent spontaneous stabilisation, seeding the surveillance-first approach.
Pancreatic neuroendocrine tumours
Richter transformation of chronic lymphocytic leukaemia
Unresectable stage III non-small-cell lung cancer
Myeloproliferative neoplasms (PV, ET, myelofibrosis). COMFORT-I/II: spleen and symptom benefit in myelofibrosis; the first JAK inhibitor.
Primary myelofibrosis
EBV-positive diffuse large B-cell lymphoma. A direct comparison found the virus in 7 per cent of 136 Mexican diffuse large B-cell lymphomas against 2 per cent of 169 German ones, w...
Triple-negative breast cancer (TNBC). Lehmann and colleagues, 587 tumours: basal-like 1 and 2, immunomodulatory, mesenchymal, mesenchymal stem-like, luminal androgen receptor; refi...
Seminoma
Lung cancer (all types). 53,454 Americans aged 55 to 74 with 30 or more pack-years were randomised to three annual low-dose CT scans or chest radiographs: 20.0 percent fewer lung c...
Ependymoma. Witt and colleagues (Cancer Cell) separate PF-A and PF-B by expression.
Medullary thyroid cancer
Thyroid cancer
BRAF V600E-mutant colorectal cancer
Epithelioid haemangioendothelioma
Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma). Tanas and colleagues, Sci Transl Med; Errani and colleagues.
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
Chicago, IL
Burlington, Massachusetts, United States
Palo Alto, CA
San Francisco, CA
Shanghai
Vienna
Suzhou
Irvine, CA
Tokyo
Taipei
The founded year on journal records.
Springer Nature (Nature Portfolio)
American Association for Cancer Research
Elsevier
Springer
SAGE Publications
Elsevier
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
Nature Reviews Cancer
Pediatric Blood & Cancer
Gynecologic Oncology
NEJM
Lancet
Nature Genetics
Cancers
Science
New England Journal of Medicine
HPB Surgery
Computerized Medical Imaging and Graphics
Lancet Oncology
Annals of Oncology
NEJM
JCO
NEJM
JCO
Breast Cancer Research and Treatment
Nutrition
Cancer Cell
Nature
Cancer Cell
JAMA
Lancet
Blood
Primary care diabetes
Nature Reviews Clinical Oncology
Eur J Anaesthesiol
Journal of Clinical Oncology
Clinical Nutrition
Cancer Science
Journal of Clinical Oncology
Journal of Clinical Oncology
Science
Annals of Internal Medicine
Journal of Clinical Oncology
NEJM
Interact Cardiovasc Thorac Surg
Lancet
Nature
Annals of Oncology
Nature
Proceedings of the National Academy of Sciences
Molecular Oncology
The Lancet Oncology
JAMA